Kintegral Advisory’s Covetrus, Inc. Common Stock CVET Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-15,806
Closed -$330K 330
2022
Q3
$330K Hold
15,806
0.05% 241
2022
Q2
$328K Buy
15,806
+335
+2% +$5.96K 0.04% 248
2022
Q1
$260K Buy
15,471
+346
+2% +$6.05K 0.03% 259
2021
Q4
$302K Hold
15,125
0.03% 257
2021
Q3
$274K Hold
15,125
0.03% 259
2021
Q2
$408K Hold
15,125
0.05% 248
2021
Q1
$453K Hold
15,125
0.06% 237
2020
Q4
$435K Hold
15,125
0.06% 233
2020
Q3
$369K Sell
15,125
-487
-3% -$10.5K 0.06% 232
2020
Q2
$279K Hold
15,612
0.04% 250
2020
Q1
$127K Buy
15,612
+1,747
+13% +$20K 0.02% 260
2019
Q4
$183K Hold
13,865
0.03% 266
2019
Q3
$165K Hold
13,865
0.03% 268
2019
Q2
$339K Hold
13,865
0.07% 238
2019
Q1
$442K Buy
+13,865
New +$492K 0.09% 204

Other funds holding CVET

Kintegral Advisory's CVET Position: Q4 2022 in Review

Kintegral Advisory sold out of Covetrus, Inc. Common Stock (CVET) in Q4 2022, closing a stake of 15,806 shares — an estimated $330K sold.

Kintegral Advisory first reported a position in CVET in Q1 2019 and held it in 15 quarters. The position peaked at $453K in Q1 2021. 5 funds tracked by Wall St. Rank hold CVET as of Q4 2022.

  • Kintegral Advisory reported no remaining Covetrus, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Kintegral Advisory sold 15,806 Covetrus, Inc. Common Stock shares in Q4 2022, an estimated $330K.
  • Kintegral Advisory first reported a position in Covetrus, Inc. Common Stock in Q1 2019 and held it in 15 quarters.
  • Kintegral Advisory's Covetrus, Inc. Common Stock position peaked at $453K in Q1 2021.
  • 5 funds tracked by Wall St. Rank held Covetrus, Inc. Common Stock as of Q4 2022.

Based on Kintegral Advisory's 13F filing for Q4 2022, filed 14 Feb 2023.